Article Type
Article
Changed
Fri, 03/22/2024 - 10:44
Display Headline
Cancer Data Trends 2024: B-Cell Lymphoma

Click to view more from Cancer Data Trends 2024.

References

  1. Lu W, Chen W, Zhou Y, et al. A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images. Sci Rep. 2023;13(1):3346. doi:10.1038/s41598-023-30533-y 

  1. Leukemia - Chronic lymphocytic - CLL: statistics. Cancer.net. Published February 2023. Accessed January 24, 2024. https://www.cancer.net/cancer-types/leukemia-chronic-lymphocytic-cll/statistics  

  1. Harmanen M, Hujo M, Sund R, et al. Survival of patients with mantle cell lymphoma in the rituximab era: retrospective binational analysis between 2000 and 2020. Br J Haematol. 2023;201(1):64-74. doi:10.1111/bjh.18597 

  1. Romancik JT, Cohen JB. Management of older adults with mantle cell lymphoma. Drugs Aging. 2020;37(7):469-481. doi:10.1007/s40266-020-00765-y 

  1. Marginal zone lymphoma (MZL). Leukemia and Lymphoma Society. Accessed January 24, 2024. https://www.lls.org/research/marginal-zone-lymphoma-mzl 

  1. Understanding lymphoma: diffuse large B-cell lymphoma. Lymphoma Research Foundation fact sheet. Updated 2023. Accessed January 24, 2024 https://lymphoma.org/wp-content/uploads/2023/10/LRF_Understanding_Lymphoma_Diffuse_Large_B_Cell_Lymphoma_Fact_Sheet.pdf 

  1. Key statistics for non-Hodgkin lymphoma. American Cancer Society. Updated January 17, 2024. Accessed January 24, 2024. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html

  1. Zullig LL, Raska W, McWhirter G, et al. Veterans Health Administration National TeleOncology Service. JCO Oncol Pract. 2023;19(4):e504-e510. doi:10.1200/OP.22.00455 

  1. Lin C, Zhou KI, Burningham ZR, et al. Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service. J Clin Oncol. 2023;41(16 suppl)16:Abstract 1602. doi:10.1200/JCO.2023.41.16_suppl.1602 

  1.  Zhang MC, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705-1716.e5. doi:10.1016/j.ccell.2023.09.004 

  1. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33-44. doi:10.1056/NEJMoa2300696 

  1. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7 

  1. Caribou Biosciences reports positive clinical data from dose escalation of CB-010 ANTLER phase 1 trial in r/r B-NHL [news release]. Globalnewswire.com. Published July 13, 2023. Accessed January 24, 2024. https://www.globenewswire.com/news-release/2023/07/13/2704702/0/en/Caribou-Biosciences-Reports-Positive-Clinical-Data-from-Dose-Escalation-of-CB-010-ANTLER-Phase-1-Trial-in-r-r-B-NHL.html 

  1. Ma J, Mo Y, Tang M, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. doi:10.3389/fimmu.2021.626616 

  1. Davis JA, Granger K, Sakowski A, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert Rev Hematol. 2023;16(12):915-918. doi:10.1080/17474086.2023.2285978 

  1. Lynch RC, Poh C, Ujjani CS, et al. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023;7(11):2449-2458. doi:10.1182/bloodadvances.2022009145 

  1. Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 2023;141(26):3137-3142. doi:10.1182/blood.2023020240 

  1. US Food and Drug Administration. FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. Published January 19, 2023. Accessed January 24, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma 

  1. US Food and Drug Administration. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Published June 16, 2023. Accessed January 24, 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell 

Author and Disclosure Information

Reviewed by Thomas Rodgers, MD
Assistant Professor, Department of Medicine
Duke University
Staff Physician, Department of Medicine
Durham VA Health System
Durham, NC

Dr. Rodgers  has no relevant financial relationships to disclose. 

Publications
Federal Practitioner
Topics
Cancer
Hematologic Malignancies
Author and Disclosure Information

Reviewed by Thomas Rodgers, MD
Assistant Professor, Department of Medicine
Duke University
Staff Physician, Department of Medicine
Durham VA Health System
Durham, NC

Dr. Rodgers  has no relevant financial relationships to disclose. 

Author and Disclosure Information

Reviewed by Thomas Rodgers, MD
Assistant Professor, Department of Medicine
Duke University
Staff Physician, Department of Medicine
Durham VA Health System
Durham, NC

Dr. Rodgers  has no relevant financial relationships to disclose. 

Click to view more from Cancer Data Trends 2024.

Click to view more from Cancer Data Trends 2024.

References

  1. Lu W, Chen W, Zhou Y, et al. A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images. Sci Rep. 2023;13(1):3346. doi:10.1038/s41598-023-30533-y 

  1. Leukemia - Chronic lymphocytic - CLL: statistics. Cancer.net. Published February 2023. Accessed January 24, 2024. https://www.cancer.net/cancer-types/leukemia-chronic-lymphocytic-cll/statistics  

  1. Harmanen M, Hujo M, Sund R, et al. Survival of patients with mantle cell lymphoma in the rituximab era: retrospective binational analysis between 2000 and 2020. Br J Haematol. 2023;201(1):64-74. doi:10.1111/bjh.18597 

  1. Romancik JT, Cohen JB. Management of older adults with mantle cell lymphoma. Drugs Aging. 2020;37(7):469-481. doi:10.1007/s40266-020-00765-y 

  1. Marginal zone lymphoma (MZL). Leukemia and Lymphoma Society. Accessed January 24, 2024. https://www.lls.org/research/marginal-zone-lymphoma-mzl 

  1. Understanding lymphoma: diffuse large B-cell lymphoma. Lymphoma Research Foundation fact sheet. Updated 2023. Accessed January 24, 2024 https://lymphoma.org/wp-content/uploads/2023/10/LRF_Understanding_Lymphoma_Diffuse_Large_B_Cell_Lymphoma_Fact_Sheet.pdf 

  1. Key statistics for non-Hodgkin lymphoma. American Cancer Society. Updated January 17, 2024. Accessed January 24, 2024. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html

  1. Zullig LL, Raska W, McWhirter G, et al. Veterans Health Administration National TeleOncology Service. JCO Oncol Pract. 2023;19(4):e504-e510. doi:10.1200/OP.22.00455 

  1. Lin C, Zhou KI, Burningham ZR, et al. Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service. J Clin Oncol. 2023;41(16 suppl)16:Abstract 1602. doi:10.1200/JCO.2023.41.16_suppl.1602 

  1.  Zhang MC, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705-1716.e5. doi:10.1016/j.ccell.2023.09.004 

  1. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33-44. doi:10.1056/NEJMoa2300696 

  1. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7 

  1. Caribou Biosciences reports positive clinical data from dose escalation of CB-010 ANTLER phase 1 trial in r/r B-NHL [news release]. Globalnewswire.com. Published July 13, 2023. Accessed January 24, 2024. https://www.globenewswire.com/news-release/2023/07/13/2704702/0/en/Caribou-Biosciences-Reports-Positive-Clinical-Data-from-Dose-Escalation-of-CB-010-ANTLER-Phase-1-Trial-in-r-r-B-NHL.html 

  1. Ma J, Mo Y, Tang M, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. doi:10.3389/fimmu.2021.626616 

  1. Davis JA, Granger K, Sakowski A, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert Rev Hematol. 2023;16(12):915-918. doi:10.1080/17474086.2023.2285978 

  1. Lynch RC, Poh C, Ujjani CS, et al. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023;7(11):2449-2458. doi:10.1182/bloodadvances.2022009145 

  1. Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 2023;141(26):3137-3142. doi:10.1182/blood.2023020240 

  1. US Food and Drug Administration. FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. Published January 19, 2023. Accessed January 24, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma 

  1. US Food and Drug Administration. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Published June 16, 2023. Accessed January 24, 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell 

References

  1. Lu W, Chen W, Zhou Y, et al. A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images. Sci Rep. 2023;13(1):3346. doi:10.1038/s41598-023-30533-y 

  1. Leukemia - Chronic lymphocytic - CLL: statistics. Cancer.net. Published February 2023. Accessed January 24, 2024. https://www.cancer.net/cancer-types/leukemia-chronic-lymphocytic-cll/statistics  

  1. Harmanen M, Hujo M, Sund R, et al. Survival of patients with mantle cell lymphoma in the rituximab era: retrospective binational analysis between 2000 and 2020. Br J Haematol. 2023;201(1):64-74. doi:10.1111/bjh.18597 

  1. Romancik JT, Cohen JB. Management of older adults with mantle cell lymphoma. Drugs Aging. 2020;37(7):469-481. doi:10.1007/s40266-020-00765-y 

  1. Marginal zone lymphoma (MZL). Leukemia and Lymphoma Society. Accessed January 24, 2024. https://www.lls.org/research/marginal-zone-lymphoma-mzl 

  1. Understanding lymphoma: diffuse large B-cell lymphoma. Lymphoma Research Foundation fact sheet. Updated 2023. Accessed January 24, 2024 https://lymphoma.org/wp-content/uploads/2023/10/LRF_Understanding_Lymphoma_Diffuse_Large_B_Cell_Lymphoma_Fact_Sheet.pdf 

  1. Key statistics for non-Hodgkin lymphoma. American Cancer Society. Updated January 17, 2024. Accessed January 24, 2024. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html

  1. Zullig LL, Raska W, McWhirter G, et al. Veterans Health Administration National TeleOncology Service. JCO Oncol Pract. 2023;19(4):e504-e510. doi:10.1200/OP.22.00455 

  1. Lin C, Zhou KI, Burningham ZR, et al. Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service. J Clin Oncol. 2023;41(16 suppl)16:Abstract 1602. doi:10.1200/JCO.2023.41.16_suppl.1602 

  1.  Zhang MC, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705-1716.e5. doi:10.1016/j.ccell.2023.09.004 

  1. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33-44. doi:10.1056/NEJMoa2300696 

  1. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7 

  1. Caribou Biosciences reports positive clinical data from dose escalation of CB-010 ANTLER phase 1 trial in r/r B-NHL [news release]. Globalnewswire.com. Published July 13, 2023. Accessed January 24, 2024. https://www.globenewswire.com/news-release/2023/07/13/2704702/0/en/Caribou-Biosciences-Reports-Positive-Clinical-Data-from-Dose-Escalation-of-CB-010-ANTLER-Phase-1-Trial-in-r-r-B-NHL.html 

  1. Ma J, Mo Y, Tang M, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. doi:10.3389/fimmu.2021.626616 

  1. Davis JA, Granger K, Sakowski A, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert Rev Hematol. 2023;16(12):915-918. doi:10.1080/17474086.2023.2285978 

  1. Lynch RC, Poh C, Ujjani CS, et al. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023;7(11):2449-2458. doi:10.1182/bloodadvances.2022009145 

  1. Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 2023;141(26):3137-3142. doi:10.1182/blood.2023020240 

  1. US Food and Drug Administration. FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. Published January 19, 2023. Accessed January 24, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma 

  1. US Food and Drug Administration. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Published June 16, 2023. Accessed January 24, 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell 

Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Cancer
Hematologic Malignancies
Article Type
Article
Display Headline
Cancer Data Trends 2024: B-Cell Lymphoma
Display Headline
Cancer Data Trends 2024: B-Cell Lymphoma
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Slideshow
Use ProPublica
CFC Schedule Remove Status
Thu, 03/14/2024 - 13:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Slide
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media
Caption
<p>Telehealth can be a valuable option for veterans living in rural areas with limited access to in-person VA care.<sup>9</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>While data on the efficacy of telehealth are mostly limited to surveillance and oral therapy, a recent small study of veterans with aggressive lymphoma showed no significant differences in care between patients receiving infusional chemoimmunotherapy administered by an in-person VA oncologist or under the direction of a remote teleoncologist through the VA's National TeleOncology program (NTO).<sup>10</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p><sup>CRR, complete response rate; ORR, overall response rate; OS, overall survival;&nbsp;R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP-X, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone combined with targeted agents</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p><sup>BTKi, Bruton tyrosine kinase inhibitor; r/r, relapsed/refractory</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p><sup>CAR-T, chimeric antigen receptor T-cell</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p><sup>BiTE, bispecific T-cell engager</sup></p>
Disable zoom
Off
Media Folder
Media Root